Mike Kratky
Stock Analyst at Leerink Partners
Total Price Targets
9
Stocks Covered
7
Sectors
Healthcare
Most Recent
Mar 10, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Mike Kratky
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| MDT | Medtronic plc | $119.00 | $80.42 | +48.0% | 2 | Mar 10, 2026 |
| VCEL | Vericel Corporation | $46.00 | $35.61 | +29.2% | 1 | Mar 10, 2026 |
| PEN | Penumbra, Inc. | $374.00 | $325.86 | +14.8% | 2 | Jan 16, 2026 |
| DXCM | DexCom, Inc. | $92.00 | $61.51 | +49.6% | 1 | Dec 16, 2025 |
| NPCE | NeuroPace, Inc. | $19.00 | $17.04 | +11.5% | 1 | Nov 5, 2025 |
| PRCT | PROCEPT BioRobotics Corporation | $55.00 | $24.27 | +126.6% | 1 | Nov 5, 2025 |
| BSX | Boston Scientific Corporation | $118.00 | $56.91 | +107.4% | 1 | Jun 16, 2025 |
Recent Activity
- Mar 10, 2026— Set$119.00price target onMDT(Medtronic plc)
- Mar 10, 2026— Set$46.00price target onVCEL(Vericel Corporation)
- Jan 16, 2026— Set$374.00price target onPEN(Penumbra, Inc.)
- Dec 16, 2025— Set$92.00price target onDXCM(DexCom, Inc.)
- Nov 19, 2025— Set$120.00price target onMDT(Medtronic plc)
- Nov 5, 2025— Set$19.00price target onNPCE(NeuroPace, Inc.)
- Nov 5, 2025— Set$55.00price target onPRCT(PROCEPT BioRobotics Corporation)
- Jun 16, 2025— Set$118.00price target onBSX(Boston Scientific Corporation)
- Sep 3, 2024— Set$263.00price target onPEN(Penumbra, Inc.)
Frequently Asked Questions
Who is Mike Kratky?
Mike Kratky is a stock analyst at Leerink Partners covering 7 stocks primarily in Healthcare. They have issued 9 price targets since Sep 3, 2024.
What stocks does Mike Kratky cover?
Mike Kratky currently covers 7 stocks, including MDT, PEN, VCEL, DXCM, NPCE.
What is Mike Kratky's latest price target?
Mike Kratky's most recent price target was $119.00 on MDT (Medtronic plc), set on Mar 10, 2026.
What is Mike Kratky's highest price target?
Mike Kratky's highest issued price target is $374.00 on PEN, set on Jan 16, 2026.
More Analysts at Leerink Partners
Coverage based on publicly published price targets. Not investment advice.